Irul

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Ŋ	y in the chile braies in the an	D IICADEM	ARK OFFICE					
	••		1614 To be assigned					
	Mail Stop Amendments Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450							
	June 8, 2004							
	TRANSMITTAL LETTER FOR INFORMATION	ON DISCEO	SURE STATEMENT					
	Sir:							
	Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.							
	1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.							
	1.97(c). This Statement is being filed aft C.F.R. §1.97(b), but before the mailing date of: i) a fin notice of allowance under 37 C.F.R. §1.311, or iii) and in the application. This Statement is being accompanied	al action und action that ot	er 37 C.F.R. §1.113, ii) a					
	A statement as specified in 37 C.F.R. §	1.97(e) [see	below]; or					

The fee set forth in 37 C.F.R. §1.17(p).

	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
31.97(c) b	This Statement is being filed after the period specified in 37 C.F.R. ut on or before payment of the issue fee. This Statement is accompanied by a as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
] 1.9	97(e).
co	Each item of information contained in the instant information disclosure tement was first cited in any communication from a foreign patent office in a unterpart foreign application not more than three (3) months prior to the filing of a instant information disclosure statement; or
for ma int §1	No item of information contained in the instant information disclosure itement was cited in a communication from a foreign patent office in a counterpart reign application, and, to the knowledge of the person signing this certification after aking reasonable inquiry, no item of information contained in the instant formation disclosure statement was known to any individual designated in 37 C.F.R56(c) more than three (3) months prior to the filing of the instant information sclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosure counterpa in section	704(d). Each item of information contained in the accompanying information statement was cited in a communication from a foreign patent office in a rt application, which communication was not received by any individual designated 1.56(c) more than thirty (30) days prior to the filing of the accompanying

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Alan R. Stempel

Attorney for Applicant(s)

Reg. No. 28,991

class mail in an envelope addressed to:

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4868

Mail Stop Amendments Commissioner For Patents

P. O. Box 1450

Alexandria, VA 22313-1450

on June 8, 2004

Alan R. Stempel, Reg. No. 28,991

Certificate of Mailing

I hereby certify that this correspondence is being deposited

with the U.S. Postal Service with sufficient postage as first

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

AVE TRADE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/685,921

Filing Date October 15, 2003

First Named Inventor Klaus RUDOLF et al

Art Unit 1614

Examiner Name To be assigned

(Use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 1/1403

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		^{US-} 6,344,449 B1	02/05/2002	Klaus Rudolf et al	3000		
		^{US-} 5,442,044	08/15/1995	Dennis J. Hoover et al			
***************************************	***************************************	US-					
	·	US-	····		•		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
	 	US-					
		US-					
		US-					

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ 'Number ⁴ 'Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			
		WO 03/104236 A1	12/18/2003	Bristol-Myers Squibb Co.					
		DE 19911039 A1	09/14/2000	Boehringer Ingelheim Pharma	74.5.7.1.0 000.5.000.000.000.000.000.000.000.000				
***************************************	ļ	EP 0438233 A2	07/24/1991	Pfizer Inc.	**************************************				
				***************************************	**************************************				
***************************************					***************************************				

Examiner	Date	
Signature	Considered	
•		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

THE TRADE LANGE

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for fo	rm 1449B/PTO			Complete if Known			
				Application Number	10/685,921		
INFOR	MATION D	ISCLO	SURE	Filing Date	October 15, 2003		
STATEMENT BY APPLICANT			CANT	First Named Inventor	Klaus RUDOLF et al		
				Art Unit	1614		
(L	lse as many sheets a	as necessary)	Examiner Name	To be assigned		
Sheet	2	of	2	Attorney Docket Number	1/1403		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		HENRI DOODS ET AL; Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist; British Journal of Pharmacology (2000) Vol. 129 page 420-423; Macmillan Publishers Ltd	***********
		JOHN J. MALLEE ET AL; Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonists; The Journal of Biological Chemistry April 19, 2002 Vol. 277 No. 16 page 14294-14298; The American Society for Biochemistry and Molecular Biology, Inc.	***************************************
			_

Examiner	Date	
Signature	 Considered	

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.